NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/06/2026
Back to search
Official data from USPTO
DHANZIA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
01/06/2026
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
03/18/2025
Registration date
01/06/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/06/2026
Last transaction
01/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Zug, CH
Examiner
MAHONEY,KATHERINE AILEEN
Law office
N90
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Kiniksa Pharmaceuticals, GmbH
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
anti-inflammatories; cardiovascular pharmaceuticals; pharmaceutical preparations for the prevention and treatment of inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders; pharmaceutical preparations for the prevention and treatment of cardiac diseases and disorders; pharmaceutical preparations for the prevention and treatment of immune-mediated diseases and disorders; pharmaceutical preparations for the prevention and treatment of rare genetic diseases and disorders
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/06/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/18/2025
PUBO
PUBLISHED FOR OPPOSITION
11/18/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/12/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/22/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
10/22/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/22/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
10/22/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/22/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/14/2025
GNFR
FINAL REFUSAL E-MAILED
10/14/2025
CNFR
FINAL REFUSAL WRITTEN
10/14/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/14/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/10/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/18/2025
GNRT
NON-FINAL ACTION E-MAILED
09/18/2025
CNRT
NON-FINAL ACTION WRITTEN
09/18/2025
DOCK
ASSIGNED TO EXAMINER
08/18/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/18/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/18/2025
NWAP
NEW APPLICATION ENTERED
03/18/2025
Continuous trademark protection
Get notified about every new filing that threatens DHANZIA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.